Keyword Analysis & Research: amg510

cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras

The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRASG12C. The mutation, a hallmark of damage from … See more

DA: 8 PA: 21 MOZ Rank: 95

nature.com

https://www.nature.com/articles/s41586-019-1694-1

WEBOct 30, 2019 · 629 Altmetric. Metrics. KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours 1, … Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ... Publish Year: 2019

Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ...

Publish Year: 2019

DA: 96 PA: 49 MOZ Rank: 91

acs.org

https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01180

WEBDiscovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. Brian A. Lanman* , Jennifer R. Allen. , John G. Allen. , Albert K. Amegadzie. , … Author: B.A. Lanman, J.R. Allen, J.G. Allen, A.K. Amegadzie, K.S. Ashton, S.K. Booker, J.J. Chen, N. Chen, M... Publish Year: 2019

Author: B.A. Lanman, J.R. Allen, J.G. Allen, A.K. Amegadzie, K.S. Ashton, S.K. Booker, J.J. Chen, N. Chen, M...

Publish Year: 2019

DA: 39 PA: 67 MOZ Rank: 17

nih.gov

https://pubmed.ncbi.nlm.nih.gov/31666701/

WEBDOI: 10.1038/s41586-019-1694-1. Abstract. KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours 1,2. The KRAS (G12C) mutant … Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ... Publish Year: 2019

Author: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, ...

Publish Year: 2019

DA: 37 PA: 45 MOZ Rank: 41

ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3511

WEBMay 25, 2020. CodeBreak 100: Phase I study of AMG 510, a novel KRAS G12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) … Author: David S. Hong, James Kuo, Adrian G. Sacher, Fabrice Barlesi, Benjamin Besse, Yasutoshi Kuboki, Grace... Publish Year: 2020

Author: David S. Hong, James Kuo, Adrian G. Sacher, Fabrice Barlesi, Benjamin Besse, Yasutoshi Kuboki, Grace...

Publish Year: 2020

DA: 28 PA: 51 MOZ Rank: 5

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504654/

WEBOct 7, 2021 · Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer - PMC. Journal List. Lung Cancer (Auckl) v.12; 2021. PMC8504654. As a …

DA: 22 PA: 7 MOZ Rank: 79

nature.com

https://www.nature.com/articles/s41401-023-01194-4

WEBDec 4, 2023 · Among them, sotorasib (also known as AMG510) and adagrasib (MRTX849) have been accelerated approval by the U.S. Food and Drug Administration (FDA) in May …

DA: 93 PA: 90 MOZ Rank: 44

nature.com

https://www.nature.com/articles/s41392-021-00780-4

WEBNov 15, 2021 · Excitingly, AMG510 was the first drug-targeting KRAS (G12C) to be approved for clinical use this year. This review summarises the most recent …

DA: 28 PA: 70 MOZ Rank: 51

amgen.com

https://www.amgen.com/newsroom/press-releases/2019/10/the-discovery-of-amgens-novel-investigational-krasg12c-inhibitor-amg-510-published-in-nature

WEBThe U.S. Food and Drug Administration ( FDA) granted Orphan Drug Designation to AMG 510 for previously treated metastatic non-small cell lung cancer (NSCLC) and colorectal …

DA: 52 PA: 49 MOZ Rank: 89

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2103695

WEBJun 4, 2021 · Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma, International Journal of …

DA: 41 PA: 28 MOZ Rank: 96